A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)

Chronic Myeloid Leukemia Clinical Trial

— READIT  

Official title:

Prospective Non-randomized Stratified Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) in Adults With Ph+ Chronic Myeloid Leukemia With Stable Deep Molecular Response

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04578847
• Other study ID #: READIT-2020
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: January 15, 2020
• Est. completion date: January 15, 2025

Study information

• Verified date: October 2020
• Source: National Research Center for Hematology, Russia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main goal of this study is to evaluate the stability of molecular response (major and deep molecular response( MMR and DMR)) in patients with chronic myeloid leukemia (CML) with stable DMR after two-stage dose reduction phase and discontinuation treatment TKI: imatinib, nilotinib, dasatinib and bosutinib.

Description:

The duration of the dose reduction phase will be 12 months. This phase will have two stage of 6 months, respectively.

The dose of imatinib, nilotinib, dasatinib or bosutinib will be reduced by 25-50% on the first stage, and by another 25% on the second stage.

• The initial dose of imatinib will be 400 mg daily. The dose will be reduced by 300 mg daily on the first stage, by 200 mg daily - on the second stage.

• The initial dose of nilotinib will be 300 or 400 mg twice daily. The dose will be reduced by 400 mg daily on the first stage, by 200 mg daily - on the second stage.

• The initial dose of dasatinib will be 100 or 140 mg daily. The dose will be reduced by 50 mg daily on the first stage, by 25 mg daily - on the second stage.

• The initial dose of bosutinib will be 500 mg daily. The dose will be reduced by 300 mg daily on the first stage, by 200 mg daily - on the second stage.

All patients with stable deep molecular response (at least 2 years) will be included in treatment free remission phase (TFR-phase). The duration of TFR-phase will be 24 months.

The CML patients can enter the study already on reduced doses TKI, if they will meet the inclusion criteria.

It is possible to include patients, who have already received therapy with reduced doses of TKI. The duration of TKI therapy with reduced doses of 1 stage should be at least 6 months, if TKI doses meet of stage 1. The duration of TKI therapy with reduced doses of 2 stage should be for at least 6 months and the general duration of TKI therapy with reduced doses should be for at least 12 months, if TKI doses meet of stage 2.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 100
• Est. completion date: January 15, 2025
• Est. primary completion date: January 15, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. CML in chronic phase.

2. TKI treatment for at least 3 years.

3. DMR (BCR-ABL=0.01%) for at least 1 year, MMR (BCR-ABL=0.1%) for at least 2 years

4. At least 3 molecular results over the preceding 24 months, which confirm the presence of MMR and DMR

5. Written Informed Consent

6. CML patients with DMR for at least 1 years and MMR for at least 2 years after STOP TKI in anamnesis.

For patients who are on the reduced dose TKI (1 stage) at the time of inclusion in the study

1. The duration of therapy at reduced doses of TKI phase I is at least 6 months.

For patients on the reduced dose TKI (2 stage, before TFR phase) at the time of inclusion in the study

1. DMR (BCR-ABL=0.01%) for at least 2 years

2. The duration of therapy at reduced doses of TKI phase 1 is for at least 6 months, the total duration of therapy at reduced doses is for at least 12 months.

Exclusion Criteria:

1. Age under 18

2. ECOG >2

3. CML in accelerated phase or blast crisis at any time

4. Lack of Written Informed Consent

5. Pregnant or lactating women

6. Incapacity

Related Conditions & MeSH terms

• BCR-ABL Positive Chronic Myelogenous Leukemia
• Chronic Myeloid Leukemia
• Chronic Myeloid Leukemia in Remission
• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid

Intervention

Drug:
• Imatinib
Initial dose - 400 mg daily. If on imatinib, the dose should be decreased to 300 mg daily on the first stage, to 200 mg daily - on the second stage.
• Nilotinib
Initial dose - 300 or 400 mg twice daily. If on nilotinib to 400mg daily on the first stage, to 200 mg daily - on the second stage.
• Dasatinib
Initial dose 100 or 140 mg daily. If on dasatinib then to 50 mg daily on the first stage, to 25 mg daily - on the second stage.
• Bosutinib
Initial dose 500 mg daily. If on bosutinib, the dose should be reduced to 300 mg daily on the first stage, to 200 mg daily on the second stage.

Locations

Country	Name	City	State
Russian Federation	National Research Center for Hematology	Moscow

Sponsors (1)

Lead Sponsor	Collaborator
National Research Center for Hematology, Russia

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival, survival without molecular relapse		37 months
Secondary	The proportion of patients with molecular relapse who achieved MMR and DMR after the resumption TKI therapy in standard doses		37 months
Secondary	The proportion of patients who resolved the adverse events after TKI dose reduction and discontinuation of TKI therapy		37 months
Secondary	The proportion of patients who have TKI withdrawal syndrome after TKI dose reduction and discontinuation of TKI therapy.		37 months
Secondary	Clinical factors, that affect the preservation of MMR after TKI dose reduction and discontinuation of therapy TKI.	sex (male, female)	37 months
Secondary	Clinical factor, that affect the preservation of MMR after TKI dose reduction and discontinuation of therapy TKI.	age	37 months
Secondary	Clinical factor, that affect the preservation of MMR after TKI dose reduction and discontinuation of therapy TKI.	risk group (Sokal, ELTS) at the time of diagnosis	37 months
Secondary	Clinical factor, that affect the preservation of MMR after TKI dose reduction and discontinuation of therapy TKI.	duration of previous TKI treatment	37 months
Secondary	Biological factor, that affect the preservation of MMR after TKI dose reduction and discontinuation of therapy TKI.	Duration of molecular response	37 months
Secondary	Biological factor, that affect the preservation of MMR after TKI dose reduction and discontinuation of therapy TKI.	Molecular response at the time of inclusion in the study	37 months